Class 3 recall- Cyanocobalamin 50mcg tablets (Glenmark Livery

Glenmark Pharmaceuticals Europe Ltd is recalling the affected batches as a precautionary measure due to out of specification results for unknown impurities during routine stability testing and additional re-testing.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-glenmark-pharmaceuticals-europe-ltd-cyanocobalamin-50-mcg-tablets-el-24-a-slash-46?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=856d3399-61cb-46ab-badf-8fa8c84a1e83&utm_content=immediately

Further Information

For medical information enquiries please use the following options by phone +44 8004 580 383 or email medical_information@glenmarkpharma.com.

For stock control enquiries please email orders.uk@glenmarkpharma.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Rosuvastatin 20mg & 40mg Sandoz

Sandoz Ltd. has informed the MHRA that there is missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for Rosuvastatin 20mg and 40mg Tablets.

MHRA Drug alert date: 1st October 2024

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-sandoz-ltd-dot-rosuvastatin-20mg-40mg-tablets-el-24-a-slash-45

This is a caution in use only we are not accepting stock returns

Further Information

For medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101.

For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607.

Class 4 caution in use-Risperidone 1mg, 2mg & 3mg tablets

Sandoz Ltd. has informed the MHRA that there is missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for Risperidone 1mg, 2mg and 3mg and Tablets.

MHRA Drug alert date: 26th September 2024

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-sandoz-ltd-dot-risperidone-1mg-2mg-3mg-tablets-el-24-a-slash-43?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=b4d60715-056e-4313-977a-7a57a225af0e&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101.

For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607.

Celebrating World Pharmacists Day

Today we recognise pharmacists like Alphega Pharmacy member Ash Jamnadass for their expert healthcare support to patients.

Marie Evans, Managing Director of Alliance Healthcare UK, said: “World Pharmacist Day is an opportunity to celebrate the dedication and passion of pharmacists, who play a vital role in transforming healthcare and supporting communities around the world. Whether it’s providing expert advice, ensuring the safe use of medicines, or delivering compassionate care, pharmacists embody the very best of our profession. At Alliance Healthcare, we are committed to honouring the difference they make every day, and celebrating the incredible work they do to improve lives and promote healthier communities”

Field safety notice-Lacri-lube eye ointment

We have received a field safety notice from Abbvie Ltd on two batches of Lacri-lube

Date of recall:19/09/24

Reason: The impacted lots may contain a breach in the tube seal

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall-Eldepryl 5mg tabs

Orion Pharma (UK) Ltd is recalling this batch as a precautionary measure due to an out of specification result in the assay result during the follow up stability study of the batch.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-orion-pharma-uk-ltd-eldepryl-5mg-tablets-selegiline-el-24-a-slash-42?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=0458c22f-f91b-4964-94a8-801ea7ca1fbe&utm_content=immediately

Further Information

For medical information enquiries please email UK.MedicalInformation@orionpharma.com, or telephone 01635 520300.

For stock control enquiries please email orionukar&customerservices@orionpharma.com.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 3 recall-Evorel Sequi patches

Theramex has informed the MHRA that some cartons of Evorel Sequi contain the incorrect combination of patches. An error at the packaging site means that a limited number of packs have the incorrect combination of Evorel 50 and Evorel Conti patches.

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-theramex-hq-uk-ltd-evorel-sequi-el-24-a-slash-41?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=07ebe937-6424-4864-9e95-99798efa4de8&utm_content=immediate

Further Information

For medical information enquiries please contact the Theramex Medical Information Department via medinfo.uk@theramex.com or call 0333 009 6795.

For stock control enquiries please contact Alliance Customer Services Team on 0330 100 0448.

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

CLASS 4 CAUTION IN USE - Ponstan 250mg Capsules & Ponstan Forte 500mg Tablets

CLASS 4 CAUTION IN USE - Ponstan 250mg Capsules & Ponstan Forte 500mg Tablets

Chemidex pharma ltd has informed the MHRA that the patient information leaflet (PIL) in the cartons for the batches listed in the tables above for Ponstan 250mg capsules and Ponstan Forte 500mg tablets include an out of date PIL, dated March 2020 and January 2021 respectively. The latest PIL, authorised in February 2023 includes updated information related to the use of the product during pregnancy, which is not mentioned in the out of date PILs.” 

MHRA Drug alert date: 27th August 2024

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-chemidex-pharma-ltd-ponstan-250mg-capsules-and-500mg-tablets-mefenamic-acid-el-24-a-slash-40?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=971b62a0-6294-430f-8887-9e276c779eb6&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please email essentialpharmaUK@EU.ProPharmaGroup.com , or telephone +44 (0)1423 850700.

For stock control enquiries please email commercial@essentialpharmagroup.com.

Class 3 Recall - FINGOLIMOD CAP 0.5MG Active

Class 3 Recall - FINGOLIMOD CAP 0.5MG

Glenmark Pharmaceuticals Europe Ltd is recalling the above batches after retesting showed out of specification results. The tabled batches are being recalled as a precautionary measure after testing showed variability of the capsule contents beyond permitted levels 

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-glenmark-pharmaceuticals-europe-ltd-fingolimod-0-dot-5-mg-hard-capsules-el-24-a-slash-39?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=84383e4c-1c50-4c97-be85-13a3b91a3aa1&utm_content=immediately

Further Information For medical information enquiries please use the following options: by phone +44 8004 580 383 or email medical_information@glenmarkpharma.com

For medical information enquiries please email dl-drugsafety@strides.com and DL-GPV-Group@arcolab.com or telephone 01923 255580.

For stock control enquiries please email orders.uk@glenmarkpharma.com

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Alliance Healthcare Team Member, Fran Middleton, Competes at European Transplant Sport Championships

Alliance Healthcare is proud to announce that Fran Middleton, a dedicated Driver Development Coach from the Hinckley team, recently represented Great Britain and Northern Ireland at the European Transplant Sport Championships (ETSC) in Lisbon, Portugal. Fran returned with an impressive collection of accolades, including three Silver medals, one Bronze, a Team GB&NI Best Heart and Lung Team and Best Overall Team trophy.

Fran's participation in the ETSC is a testament to his resilience and dedication. After receiving a heart transplant in 2018, he has become an advocate for organ donation, raising awareness through his involvement in international sports. Last year, Fran represented Great Britain at the World Transplant Games in Perth, Australia, where he competed to honour the memory of his donor and highlight the lifesaving impact of organ transplants. To support Fran and his mission, Alliance Healthcare UK sponsored the GB volleyball team, financing their kit.

Expressing his enthusiasm for the competition, Fran said:

“The European Transplant Sports Championship Lisbon 2024 has been absolutely fantastic! I'm extremely proud and honoured to have helped manage the team, challenging at times, but hugely rewarding to play a small part in everyone's success and enjoyment. The tops were great, and the team said a huge thank you for the kind sponsorship. Thanks to everyone at AHUK who rooted for me!”

Marie Evans, Managing Director at Alliance Healthcare said:

"We are incredibly proud of Fran Middleton and his unwavering determination to not only overcome personal challenges but also to inspire others through his remarkable journey. His participation in the European Transplant Sport Championships embodies the resilience, courage, and commitment that we value at Alliance Healthcare. By supporting Fran and the GB volleyball team, we are not just backing an exceptional team member, but also promoting the vital message of organ donation and its life-saving impact."